<DOC>
	<DOCNO>NCT01631981</DOCNO>
	<brief_summary>This Phase II , multicentre , randomise , two-arm , parallel group , double-blind , placebo control , study investigate efficacy , safety , pharmacokinetics pharmacodynamics steroid sulfatase inhibitor PGL2001 concomitant , continuous NETA administration treatment pain symptom suggestive endometriosis . The target population woman reproductive age symptom suggestive endometriosis .</brief_summary>
	<brief_title>PGL2001 Proof Concept Study Symptomatic Endometriosis</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<criteria>Provide write informed consent prior initiation study related procedure . Be woman reproductive age 18 45 year inclusive . Present clinical sign suggestive endometriosis . Be suffer non menstrual pelvic pain dysmenorrhea suggestive endometriosis least 3 month prior screen visit . Be pregnant currently lactate . Have disease suspect disease may cause pelvic pain due endometriosis . Have surgical treatment endometriosis within last 12 month . Have document significant adenomyosis . Have participate another clinical trial within 30 day prior screen visit .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>